Filana Therapeutics opened lower at $0.48, compared with its previous close of $0.48. In the last trading session, the stock traded between $0.45 and $0.48. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Filana Therapeutics is now worth
$ 21.34
Resulting in a loss of
$ 78.66 (78.66%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.04 (-7.49%)
Day High
$0.48
Day Low
$0.45
Day Open
$0.48
Prev Close
$0.48
Volume
3,75,877
1W Return
-22.84%
1M Return
-41.78%
3M Return
-53.88%
6M Return
-65.16%
1Y Return
-78.66%
Fundamentals
Market Cap ($ Mn)
22
PE Ratio
-
PB Ratio
0.70
PEG Ratio
-
ROE
-87.94%
ROCE
-92.32%
EPS (TTM)
$-0.21
Investment Returns
1 Week
-22.84%
1 Month
-41.78%
3 Months
-53.88%
6 Months
-65.16%
9 Months
-78.66%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
5Nov
Filana Therapeutics Q3 Results: Loss per share narrows to $(0.22)
Filana Therapeutics reported a loss of $(0.22) per share for Q3. The result beat the analyst consensus estimate of $(0.24). Earnings per share remained unchanged from the same period last year.
7 days ago
20Oct
Fifth Circuit rules Texas court misapplied standard in Filana case
Fifth Circuit ruled Texas District Court misapplied legal standard. Ruling concerns class certification decision for Filana Therapeutics. Announcement made via SEC filing dated October 19, 2026.
23 days ago
22Sep
FDA lifts clinical hold on Filana Therapeutics' epilepsy trial
FDA lifted clinical hold on Filana Therapeutics' simufilam trial for TSC-related epilepsy. Shares of Filana Therapeutics rose 52.13% to $1.12 following the announcement. Phase 2a trial will enroll 40 participants aged 12 to 55, starting screening in Q1 2027. Company holds exclusive worldwide IP license from Yale University for this indication.
1mo ago
13Aug
Filana Therapeutics insiders probed for fiduciary duty breaches
Halper Sadeh LLC investigates Filana Therapeutics insiders for alleged fiduciary breaches. Long-term shareholders are urged to act quickly to explore legal remedies, including governance reforms and financial recovery, on a contingent fee basis.
3mo ago
29Jul
Filana Therapeutics Q2 EPS beats estimate, loss narrows 81%
Filana Therapeutics beat Q2 EPS estimates with a loss of $(0.18) per share, improving 80% YoY. The $8.6 million net loss reflects reduced R&D and the absence of a prior-year litigation charge, though $31.25 million is now held in escrow.
